Browsing by Author "Milinkovic, Vedrana (35810904900)"
Now showing 1 - 3 of 3
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Genetic alterations in quadruple malignancies of a patient with multiple sclerosis: Their role in malignancy development and response to therapy(2014) ;Milosevic, Zorica (57209726720) ;Tanic, Nikola (7801574805) ;Bankovic, Jasna (24278374400) ;Stankovic, Tijana (55321765700) ;Buta, Marko (16202214500) ;Lavrnic, Dragana (6602473221) ;Milovanovic, Zorka (25228841900) ;Pupic, Gordana (6507142544) ;Stojkovic, Sonja (55915641500) ;Milinkovic, Vedrana (35810904900) ;Ito, Yasuhiro (35427371100)Dzodic, Radan (6602410321)Multiple cancers represent 2.42% of all human cancers and are mainly double or triple cancers. Many possible causes of multiple malignancies have been reported such as genetic alterations, exposure to anti-cancer chemotherapy, radiotherapy, immunosuppressive therapy and reduced immunologic response. We report a female patient with multiple sclerosis and quadruple cancers of different embryological origin. Patient was diagnosed with stage III (T3, N1a, MO) medullary thyroid carcinoma (MTC), multicentric micropapillary thyroid carcinoma, scapular and lumbar melanomas (Clark II, Breslow II), and lobular invasive breast carcinoma (T1a, NO, MO). All tumors present in our patient except micropapillary thyroid carcinomas were investigated for gene alterations known to have a key role in cancer promotion and progression. Tumor samples were screened for the p16 alterations (loss of heterozygosity and homozygous deletions), loss of heterozygosity of PTEN, p53 alterations (mutational status and loss of heterozygosity) and mutational status of RET, HRAS and KRAS. Each type of tumor investigated had specific pattern of analyzed genetic alterations. The most prominent genetic changes were mutual alterations in PTEN and p53 tumor suppressors present in breast cancer and two melanomas. These co-alterations could be crucial for promoting development of multiple malignancies. Moreover the insertion in 4th codon of HRAS gene was common for all tumor types investigated. It represents frameshift mutation introducing stop codon at position 5 which prevents synthesis of a full-length protein. Since the inactivated RAS enhances sensitivity to tamoxifen and radiotherapy this genetic alteration could be considered as a good prognostic factor for this patient. - Some of the metrics are blocked by yourconsent settings
Publication Genomic instability and p53 alterations in patients with malignant glioma(2012) ;Milinkovic, Vedrana (35810904900) ;Bankovic, Jasna (24278374400) ;Rakic, Miodrag (24399715100) ;Milosevic, Nebojsa (35608832100) ;Stankovic, Tijana (55321765700) ;Jokovic, Milos (9238913900) ;Milosevic, Zorica (57209726720) ;Skender-Gazibara, Milica (22836997600) ;Podolski-Renic, Ana (36669235200) ;Pesic, Milica (36768679400) ;Ruzdijic, Sabera (7003935669)Tanic, Nikola (7801574805)The purpose of this study was to detect the level of genomic instability and p53 alterations in anaplastic astrocytoma and primary glioblastoma patients, and to evaluate their impact on glioma pathogenesis and patients outcome. AP-PCR DNA profiling revealed two types of genetic differences between tumor and normal tissue: qualitative changes which represent accumulation of changes in DNA sequence and are the manifestation of microsatellite and point mutation instability (MIN-PIN) and quantitative changes which represent amplifications or deletions of existing chromosomal material and are the manifestation of chromosomal instability (CIN). Both types of alterations were present in all analyzed samples contributing almost equally to the total level of genomic instability, and showing no differences between histological subtypes. p53 alterations were detected in 40% of samples, predominantly in anaplastic astrocytoma. The higher level of genomic instability was observed in elderly patients (> 50. years) and patents with primary glioblastoma. Level of genomic instability had no impact on patients' survival, while presence of p53 alterations seemed to be a favorable prognostic factor in this case. Our results indicate that extensive genomic instability is one of the main features of malignant gliomas. © 2012 Elsevier Inc. - Some of the metrics are blocked by yourconsent settings
Publication Genomic instability and p53 alterations in patients with malignant glioma(2012) ;Milinkovic, Vedrana (35810904900) ;Bankovic, Jasna (24278374400) ;Rakic, Miodrag (24399715100) ;Milosevic, Nebojsa (35608832100) ;Stankovic, Tijana (55321765700) ;Jokovic, Milos (9238913900) ;Milosevic, Zorica (57209726720) ;Skender-Gazibara, Milica (22836997600) ;Podolski-Renic, Ana (36669235200) ;Pesic, Milica (36768679400) ;Ruzdijic, Sabera (7003935669)Tanic, Nikola (7801574805)The purpose of this study was to detect the level of genomic instability and p53 alterations in anaplastic astrocytoma and primary glioblastoma patients, and to evaluate their impact on glioma pathogenesis and patients outcome. AP-PCR DNA profiling revealed two types of genetic differences between tumor and normal tissue: qualitative changes which represent accumulation of changes in DNA sequence and are the manifestation of microsatellite and point mutation instability (MIN-PIN) and quantitative changes which represent amplifications or deletions of existing chromosomal material and are the manifestation of chromosomal instability (CIN). Both types of alterations were present in all analyzed samples contributing almost equally to the total level of genomic instability, and showing no differences between histological subtypes. p53 alterations were detected in 40% of samples, predominantly in anaplastic astrocytoma. The higher level of genomic instability was observed in elderly patients (> 50. years) and patents with primary glioblastoma. Level of genomic instability had no impact on patients' survival, while presence of p53 alterations seemed to be a favorable prognostic factor in this case. Our results indicate that extensive genomic instability is one of the main features of malignant gliomas. © 2012 Elsevier Inc.